AIM ImmunoTech Inc. (LON:0A4Y)

Market Cap	1.77M -82.9%
Revenue (ttm)	83.32K -41.1%
Net Income	-11.72M
EPS	-11.08
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,831
Average Volume	39,631
Open	0.8200
Previous Close	0.9950
Day's Range	0.8200 - 0.9376
52-Week Range	0.8200 - 34.1360
Beta	1.24
RSI	33.64
Earnings Date	Mar 27, 2026

About AIM ImmunoTech

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. Its flagship products are Ampligen (rintatolimod), a drug of large macromolecular double-stranded ribonucleic acid molecules to treat chronic fatigue syndrome; and Alferon N Injection (Interferon alfa), a purified, natural-source, glycosylated, multi-species alpha interferon product for the treatment of genital warts. The company is also d...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1966
• Employees: 23
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0A4Y

Financial Performance

In 2024, AIM ImmunoTech's revenue was $170,000, a decrease of -15.84% compared to the previous year's $202,000. Losses were -$17.32 million, -40.20% less than in 2023.

Financial numbers in USD